http://www.fpnotebook.com/
TerbinafineAka: Lamisil
- See Also
- Allylamine
- Indications
- Topical Management (Lamisil)
- Resistant dermatophyte infection (e.g. Tinea Pedis)
- Systemic Management (Terbinafine)
- Onychomycosis
- Adverse Effects: Oral Terbinafine
- Uncommon effects
- Headache
- Rash
- Gastrointestinal upset
- Rare effects
- Cholestatic hepatitis
- Blood dyscrasia
- Stevens-Johnson Syndrome
- Monitoring: Oral Terbinafine
- Protocol
- Baseline labs
- Repeat every 4 to 6 weeks
- Stop agent if AST or ALT >2x normal
- Labs
- Complete Blood Count and Platelet Count
- Aspartate Aminotransferase (AST)
- Alanine Aminotransferase (ALT)
- Dosing: Oral
- Dose
- Adult (and child >40 kg): 250 mg PO qd
- Child 20-40 kg: 125 mg PO qd
- Child <20 kg: 67.5 mg PO qd
- Course in Onychomycosis
- Fingernail: 6 weeks
- Toenail: 12 weeks
- Drug Interactions
- Cimetidine increases terbinafine levels
- Rifampin decreases terbinafine levels
- Increased bleeding risk with Warfarin
- References
- Gupta (1999) J Am Acad Dermatol 41:237
- Friedlander (1999) Pediatr Infect Dis J 18(2):205
- McClellan (1999) Drugs 58(1):179
- Perez (1999) Mycoses 43:79
|
|---|
| Definition (NCI) | A synthetic allylamine derivative with antifungal activity. Terbinafine exerts its effect through inhibition of squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an important component of fungal cell membranes. As a result, this agent disrupts fungal cell membrane synthesis and inhibits fungal growth. |
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | terbinafine, TERBINAFINE PREPARATION |
| Spanish | terbinafina |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree